Design Formulation of Nanospanlastic Novel Carriers as a Promising
Approach to Enhanced Bioavailability in Intranasal Drug Delivery for
Sinusitis: Statistical Optimization and In vitro and In vivo Characterization

Ananda   Kumar   Chettupalli; Srivani      Ajmera; Mounika      Kuchukuntla; Venkatesan      Palanivel; Sunand      Katta

Abstract

Background: Most new biologically active chemicals require better water solubility and slower dissolution rates. Cefdinir (CFD) has a very low bioavailability in its crystalline form and is poorly soluble in water.

Objective: By preparing cefdinir's spanlastic nanovesicles (SNVs) using the ethanol injection method, the current study has attempted to enhance the drug's solubility and bioavailability using a statistical design approach.

Methods: Independent variables, including the nonionic surfactant concentration, edge activator (EA), sonication time, SNVs entrapment efficiency, particle size, zeta potential, PDI, and in vitro release, have been evaluated. The best CFD-SNVs were positioned within in situ gel with mucoadhesive properties made of hydroxypropyl methylcellulose and deacetylated gellan gum. By contrasting intranasal injection of the produced gel with an IV solution, animal models have been used to investigate CFD's systemic and cerebral dynamics.

Results: Statistical analysis has suggested an ideal SNVs formulation with nonionic surfactant (65 mg), EA (15 mg), and sonication (3 min). The sol-gel temperature for forming the mucoadhesive in situ gel containing SNVs has been found to be 34.03°C, and 18.36 minutes has been the extended mucociliary transit time. Following intranasal injection, compared to SNV dispersion, the gelling system has exhibited higher brain bioavailability (2251.9 ± 75 vs. 5281.6 ± 51%, respectively). The gel has also demonstrated effective drug targeting of the brain with higher direct transport percentage indices.

Conclusion: Mucoadhesive in situ gel with CFD-loaded SNVs can be administered via the intranasal route. To enhance bioavailability in the brain and drug targeting from the nose to the brain, nasal in situ gel loaded with CFD-SNVs could be a new carrier to be employed in sinusitis.

Graphical Abstract

[1]
Guay DRP. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin. Pediatr Infect Dis J  2000; 19(12): S141-6.
 [http://dx.doi.org/10.1097/00006454-200012001-00002 ] [PMID:  11144395]

[2]
Lu Q, Zhang H, Che DT, Li WH. [In vitro antibacterial activity of cefdinir against isolates of respiratory tract pathogens in children. Zhonghua Er Ke Za Zhi  2004; 42(9): 697-700.
 [PMID: 15482675]

[3]
Guay DRP. Cefdinir: An advanced-generation, broad-spectrum oral cephalosporin. Clin Ther  2002; 24(4): 473-89.
 [http://dx.doi.org/10.1016/S0149-2918(02)85125-6 ] [PMID:  12017394]

[4]
Stuchlík M, Žák S. Lipid-based vehicle for oral drug delivery. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub  2001; 145(2): 17-26.
 [http://dx.doi.org/10.5507/bp.2001.008] [PMID:  12426768]

[5]
Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: Dermal and transdermal drug delivery. J Control Release  1994; 30(1): 1-15.
 [http://dx.doi.org/10.1016/0168-3659(94)90039-6]

[6]
Montone KT. Pathology of fungal rhinosinusitis: A review. Head Neck Pathol  2016; 10(1): 40-6.
 [http://dx.doi.org/10.1007/s12105-016-0690-0] [PMID:  26830404]

[7]
Chakrabarti A, Das A, Panda NK. Controversies surrounding the categorization of fungal sinusitis. Med Mycol  2009; 47(s1): S299-308.
 [http://dx.doi.org/10.1080/13693780802213357] [PMID:  18663658]

[8]
Kammoun AK, Khedr A, Hegazy MA, et al. Formulation, optimization, and nephrotoxicity evaluation of an antifungal in situ nasal gel loaded with voriconazole-clove oil transferosomal nanoparticles. Drug Deliv  2021; 28(1): 2229-40.
 [http://dx.doi.org/10.1080/10717544.2021.1992040 ] [PMID:  34668818]

[9]
Misra A, Jogani V, Jinturkar K, Vyas T. Recent patents review on intranasal administration for CNS drug delivery. Recent Pat Drug Deliv Formul  2008; 2(1): 25-40.
 [http://dx.doi.org/10.2174/187221108783331429] [PMID:  19075895]

[10]
Laverdiere M, Bow EJ, Rotstein C, et al. Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol  2014; 25(6): 327-43.
 [http://dx.doi.org/10.1155/2014/340586] [PMID:  25587296]

[11]
Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: Practical implications for optimized treatment of patients. Infection  2017; 45(6): 737-79.
 [http://dx.doi.org/10.1007/s15010-017-1042-z] [PMID:  28702763]

[12]
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology  2018; 16(1): 71.
 [http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID:  30231877]

[13]
Abou-Taleb HA, Khallaf RA, Abdel-Aleem JA. Intranasal niosomes of nefopam with improved bioavailability: Preparation, optimization, and in-vivo evaluation. Drug Des Devel Ther  2018; 12: 3501-16.
 [http://dx.doi.org/10.2147/DDDT.S177746] [PMID:  30410310]

[14]
Sharma A, Pahwa S, Bhati S, Kudeshia P. Spanlastics: A modern approach for nanovesicular drug delivery system. Int J Pharm Sci Res  2020; 11: 1057-65.

[15]
Shah HS, Usman F, Ashfaq-Khan M, et al. Preparation and characterization of anticancer niosomal withaferin-A formulation for improved delivery to cancer cells: in vitro, in vivo, and in silico evaluation. J Drug Deliv Sci Technol  2020; 59: 101863.
 [http://dx.doi.org/10.1016/j.jddst.2020.101863]

[16]
Parthasarathi G, Udupa N, Umadevi P, Pillai G. Niosome encapsulated of vincristine sulfate: Improved anticancer activity with reduced toxicity in mice. J Drug Target  1994; 2(2): 173-82.
 [http://dx.doi.org/10.3109/10611869409015907] [PMID:  8069596]

[17]
Zaki RM, Ibrahim MA, Alshora DH, El Ela AESA. Formulation and evaluation of transdermal gel containing tacrolimus-loaded spanlastics: In vitro, ex vivo and in vivo studies. Polymers  2022; 14(8): 1528.
 [http://dx.doi.org/10.3390/polym14081528] [PMID:  35458277]

[18]
Elhabak M, Ibrahim S, Abouelatta SM. Topical delivery of l -ascorbic acid spanlastics for stability enhancement and treatment of UVB induced damaged skin. Drug Deliv  2021; 28(1): 445-53.
 [http://dx.doi.org/10.1080/10717544.2021.1886377 ] [PMID:  33620008]

[19]
Hosny KM, Alhakamy NA, Sindi AM, Khallaf RA. Coconut oil nanoemulsion loaded with a statin hypolipidemic drug for management of burns: Ormulation and in vivo evaluation. Pharmaceutics  2020; 12(11): 1061.
 [http://dx.doi.org/10.3390/pharmaceutics12111061 ] [PMID:  33171816]

[20]
Ahmed OAA, Kurakula M, Banjar ZM, Afouna MI, Zidan AS. Quality by design coupled with near infrared in formulation of transdermal glimepiride liposomal films. J Pharm Sci  2015; 104(6): 2062-75.
 [http://dx.doi.org/10.1002/jps.24448] [PMID:  25873019]

[21]
Zhu L, Ao J, Li P. A novel in situ gel base of deacetylase gellan gum for sustained ophthalmic drug delivery of ketotifen: In vitro and in vivo evaluation. Drug Des Devel Ther  2015; 9: 3943-9.
 [PMID:  26251573]

[22]
Singh NK, Lee DS. In situ gelling pH- and temperature-sensitive biodegradable block copolymer hydrogels for drug delivery. J Control Release  2014; 193: 214-27.
 [http://dx.doi.org/10.1016/j.jconrel.2014.04.056] [PMID:  24815421]

[23]
Hamed SF, Sadek Z, Edris A. Antioxidant and antimicrobial activities of clove bud essential oil and eugenol nanoparticles in alcohol-free microemulsion. J Oleo Sci  2012; 61(11): 641-8.
 [http://dx.doi.org/10.5650/jos.61.641] [PMID:  23138253]

[24]
Darvishi E, Omidi M, Bushehri AAS, Golshani A, Smith ML. The antifungal eugenol perturbs dual aromatic and branched-chain amino acid permeases in the cytoplasmic membrane of yeast. PLoS One  2013; 8(10): e76028.
 [http://dx.doi.org/10.1371/journal.pone.0076028] [PMID:  24204588]

[25]
Lee SJ, Han JI, Lee GS, et al. Antifungal effect of eugenol and nerolidol against Microsporum gypseum in a guinea pig model. Biol Pharm Bull  2007; 30(1): 184-8.
 [http://dx.doi.org/10.1248/bpb.30.184] [PMID:  17202684]

[26]
Galgatte UC, Kumbhar AB, Chaudhari PD. Development of in situ gel for nasal delivery: Design, optimization, in vitro and in vivo evaluation. Drug Deliv  2014; 21(1): 62-73.
 [http://dx.doi.org/10.3109/10717544.2013.849778] [PMID:  24191774]

[27]
Database of select committee on GRAS substances (SCOGS) Reviews. Silver Spring, MD, USA: US Food and Drug Administration 2006.

[28]
US Food and Drug Administration.  Inactive ingredient search for approved drug products. FDA Database 2017.

[29]
Salim M, Minamikawa H, Sugimura A, Hashim R. Amphiphilic designer nano-carriers for controlled release: From drug delivery to diagnostics. MedChemComm  2014; 5(11): 1602-18.
 [http://dx.doi.org/10.1039/C4MD00085D]

[30]
Abdelbary GA, Amin MM, Zakaria MY. Ocular ketoconazole-loaded proniosomal gels: Formulation, ex vivo corneal permeation and in vivo studies. Drug Deliv  2017; 24(1): 309-19.
 [http://dx.doi.org/10.1080/10717544.2016.1247928 ] [PMID:  28165809]

[31]
Fahmy AM, El-Setouhy DA, Ibrahim AB, Habib BA, Tayel SA, Bayoumi NA. Penetration enhancer-containing spanlastics (PECSs) for transdermal delivery of haloperidol: In vitro characterization, ex vivo permeation and in vivo biodistribution studies. Drug Deliv  2018; 25(1): 12-22.
 [http://dx.doi.org/10.1080/10717544.2017.1410262 ] [PMID:  29219628]

[32]
Jaafar-Maalej C, Diab R, Andrieu V, Elaissari A, Fessi H. Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation. J Liposome Res  2010; 20(3): 228-43.
 [http://dx.doi.org/10.3109/08982100903347923] [PMID:  19899957]

[33]
Farghaly DA, Aboelwafa AA, Hamza MY, Mohamed MI. Topical delivery of fenoprofen calcium via elastic nano-vesicular spanlastics: Optimization using experimental design and in vivo evaluation. AAPS PharmSciTech  2017; 18(8): 2898-909.
 [http://dx.doi.org/10.1208/s12249-017-0771-8] [PMID:  28429293]

[34]
El Gamal SS, Naggar VF, Allam AN. Optimization of acyclovir oral tablets based on gastroretention technology: Factorial design analysis and physicochemical characterization studies. Drug Dev Ind Pharm  2011; 37(7): 855-67.
 [http://dx.doi.org/10.3109/03639045.2010.546404] [PMID:  21401342]

[35]
New RR. Liposomes: A practical approach.  In: Preparation of liposomes. IRL Press 1990.

[36]
Amarachinta PR, Sharma G, Samed N, Chettupalli AK, Alle M, Kim JC. Central composite design for the development of carvedilol-loaded transdermal ethosomal hydrogel for extended and enhanced anti-hypertensive effect. J Nanobiotechnology  2021; 19: 1-15.

[37]
Beg S, Al Robaian M, Rahman M, Imam SS, Alruwaili N, Panda SK. Pharmaceutical drug product development and process optimization: Effective use of quality by design. CRC Press 2020.
 [http://dx.doi.org/10.1201/9780367821678]

[38]
Jahangir MA, Anand C, Muheem A, et al. Nano phytomedicine based delivery system for CNS disease. Curr Drug Metab  2020; 21(9): 661-73.
 [http://dx.doi.org/10.2174/1389200221666200523161003 ] [PMID:  32445453]

[39]
Shntaif AH, Khan S, Tapadiya G, et al. Rational drug design, synthesis, and biological evaluation of novel N-(2-arylaminophenyl)-2,3-diphenylquinoxaline-6-sulfonamides as potential antimalarial, antifungal, and antibacterial agents. Digital Chinese Med  2021; 4(4): 290-304.
 [http://dx.doi.org/10.1016/j.dcmed.2021.12.004]

[40]
Jahangir MA, Imam SS, Muheem A, et al. Nanocrystals: Characterization overview, applications in drug delivery, and their toxicity concerns. J Pharm Innov  2020; 1-12.

[41]
Chettupalli AK, Ananthula M, Amarachinta PR, Bakshi V, Yata VK. Design, formulation, in-vitro and ex-vivo evaluation of atazanavir loaded cubosomal gel. Biointerface Res Appl Chem  2021; 11(4): 12037-54.

[42]
Chettupalli AK, Rao PA, Kuchukuntla M, Bakshi V. Development and optimization of aripiprazole ODT by using box-behnken design. Res J Pharma Technol  2020; 13(12): 6195-201.
 [http://dx.doi.org/10.5958/0974-360X.2020.01080.X]

[43]
Dandamudi SP, Chettupalli AK, Dargakrishna SP, Nerella M, Amara RR, Yata VK. Response Surface Method for the Simultaneous Estimation of Atorvastatin and Olmesartan. Trends Sci  2022; 19(18): 5799-9.
 [http://dx.doi.org/10.48048/tis.2022.5799]

[44]
Jahangir MA, Muheem A, Anand C, Imam SS. Traditional and modern applications of honey: An insight. In: Therapeutic Applications of Honey and its Phytochemicals.  Singapore: Springer 2020; 1: pp. 151-69.

[45]
Bakshi V, Amarachinta PR, Chettupalli AK. Design, development and optimization of solid lipid nanoparticles of rizatriptan for intranasal delivery: in vitro & in vivo assessment. Mater Today Proc  2022; 66: 2342-57.
 [http://dx.doi.org/10.1016/j.matpr.2022.06.329]

[46]
Chettupalli AK, Amara RR, Amarachinta PR, Manda RM, Garige BSR, Yata VK. Formulation and evaluation of poly herbal liqui-solid compact for its anti-inflammatory effect. Biointerface Res Appl Chem  2022; 12: 3883-9.

[47]
Al-mahallawi AM, Khowessah OM, Shoukri RA. Nano-transfersomal ciprofloxacin loaded vesicles for non-invasive trans-tympanic ototopical delivery: in-vitro optimization, ex-vivo permeation studies, and in-vivo assessment. Int J Pharm  2014; 472(1-2): 304-14.
 [http://dx.doi.org/10.1016/j.ijpharm.2014.06.041] [PMID:  24971692]

[48]
Mali N, Darandale S, Vavia P. Niosomes as a vesicular carrier for topical administration of minoxidil: Formulation and in vitro assessment. Drug Deliv Transl Res  2013; 3(6): 587-92.
 [http://dx.doi.org/10.1007/s13346-012-0083-1] [PMID:  25786376]

[49]
Bhatia M, Ahuja M. Psyllium arabinoxylan: Carboxymethylation, characterization and evaluation for nanoparticulate drug delivery. Int J Biol Macromol  2015; 72: 495-501.
 [http://dx.doi.org/10.1016/j.ijbiomac.2014.08.051] [PMID:  25199870]

[50]
Kurakula M, Ahmed TAT. Co-delivery of atorvastatin nanocrystals in PLGA based in situ gel for anti-hyperlipidemic efficacy. Curr Drug Deliv  2016; 13(2): 211-20.
 [http://dx.doi.org/10.2174/1567201813666151109102718 ] [PMID:  26549039]

[51]
Hosny KM, Rizg WY, Khallaf RA. Preparation and optimization of in situ gel loaded with rosuvastatin-ellagic acid nanotransfersomes to enhance the anti-proliferative activity. Pharmaceutics  2020; 12(3): 263.
 [http://dx.doi.org/10.3390/pharmaceutics12030263 ] [PMID:  32183144]

[52]
Chang JY, Oh YK, Choi H, Kim YB, Kim CK. Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int J Pharm  2002; 241(1): 155-63.
 [http://dx.doi.org/10.1016/S0378-5173(02)00232-6 ] [PMID:  12086731]

[53]
Kim CK, Lee SW, Choi HG, et al. Trials of in situ-gelling and mucoadhesive acetaminophen liquid suppository in human subjects. Int J Pharm  1998; 174(1-2): 201-7.
 [http://dx.doi.org/10.1016/S0378-5173(98)00258-0]

[54]
Bansal K, Rawat MK, Jain A, Rajput A, Chaturvedi TP, Singh S. Development of satranidazole mucoadhesive gel for the treatment of periodontitis. AAPS PharmSciTech  2009; 10(3): 716-23.
 [http://dx.doi.org/10.1208/s12249-009-9260-z] [PMID:  19479385]

[55]
Pathan IB, Mene H, Bairagi S. Quality by design (QbD) approach to formulate in situ gelling system for nose to brain delivery of Fluoxetine hydrochloride: Ex-vivo and In-vivo study. Ars Pharmaceut  2017; 58(3): 107-14.
 [http://dx.doi.org/10.30827/ars.v58i3.6528]

[56]
Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol  2001; 52(3): 255-64.
 [http://dx.doi.org/10.1046/j.0306-5251.2001.01452.x ] [PMID:  11560557]

[57]
El-Nabarawy NA, Teaima MH, Helal DA. Assessment of spanlastic vesicles of zolmitriptan for treating migraine in rats. Drug Des Devel Ther  2019; 13: 3929-37.
 [http://dx.doi.org/10.2147/DDDT.S220473] [PMID:  31819367]

[58]
Dalpiaz A, Marchetti N, Cavazzini A, et al. Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: Application to in vivo preclinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci  2012; 901: 72-8.
 [http://dx.doi.org/10.1016/j.jchromb.2012.06.001] [PMID:  22743338]

[59]
Chen X, Liu D, Luan Y, Jin F, Zhong D. Determination of zolmitriptan in human plasma by liquid chromatography-tandem mass spectrometry method: Application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci  2006; 832(1): 30-5.
 [http://dx.doi.org/10.1016/j.jchromb.2005.12.008] [PMID:  16413836]

[60]
Vyas TK, Babbar AK, Sharma RK, Misra A. Intranasal mucoadhesive microemulsions of zolmitriptan: Preliminary studies on brain-targeting. J Drug Target  2005; 13(5): 317-24.
 [http://dx.doi.org/10.1080/10611860500246217] [PMID:  16199375]

[61]
Jacob S, Nair AB, Al-Dhubiab BE. Preparation and evaluation of niosome gel containing acyclovir for enhanced dermal deposition. J Liposome Res  2017; 27(4): 283-92.
 [http://dx.doi.org/10.1080/08982104.2016.1224897 ] [PMID:  27558522]

[62]
Guideline IHT.  Stability testing of new drug substances and products.Q1A (R2). 2003. Available from:
          https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products

[63]
Jacob S, Nair AB, Shah J. Emerging role of nanosuspensions in drug delivery systems. Biomater Res  2020; 24(1): 3.
 [http://dx.doi.org/10.1186/s40824-020-0184-8] [PMID:  31969986]

[64]
Agrawal A, Maheshwari RK. Formulation development and evaluation of in situ nasal gel of poorly water soluble drug using mixed solvency concept. Asian J Pharm  2011; 5(3): 131.
 [http://dx.doi.org/10.4103/0973-8398.91988]

[65]
Abdelbary G, El-gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech  2008; 9(3): 740-7.
 [http://dx.doi.org/10.1208/s12249-008-9105-1] [PMID:  18563578]

[66]
Patel J, Patel D, Raval J. Formulation and evaluation of propranolol hydrochloride-loaded carbopol-934p/ethyl cellulose mucoadhesive microspheres. Iran J Pharm Res  2010; 9(3): 221-32.
 [PMID:  24363731]

[67]
Araújo J, Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm  2010; 393(1-2): 168-76.
 [http://dx.doi.org/10.1016/j.ijpharm.2010.03.034] [PMID:  20362042]

[68]
Turk CTS, Oz UC, Serim TM, Hascicek C. Formulation and optimization of nonionic surfactants emulsified nimesulide-loaded PLGA-based nanoparticles by design of experiments. AAPS PharmSciTech  2014; 15(1): 161-76.
 [http://dx.doi.org/10.1208/s12249-013-0048-9] [PMID:  24222270]

[69]
Al-mahallawi AM, Khowessah OM, Shoukri RA. Enhanced non invasive trans -tympanic delivery of ciprofloxacin through encapsulation into nano-spanlastic vesicles: Fabrication, in-vitro characterization, and comparative ex-vivo permeation studies. Int J Pharm  2017; 522(1-2): 157-64.
 [http://dx.doi.org/10.1016/j.ijpharm.2017.03.005] [PMID:  28279741]

[70]
Kao LS, Green CE. Analysis of variance: Is there a difference in means and what does it mean? J Surg Res  2008; 144(1): 158-70.
 [http://dx.doi.org/10.1016/j.jss.2007.02.053] [PMID:  17936790]

[71]
Petchsomrit A, Sermkaew N, Wiwattanapatapee R. Effect of alginate and surfactant on physical properties of oil entrapped alginate bead formulation of curcumin. Int J Pharm Pharm Sci  2013; 7(12): 864-8.

[72]
Danaei M, Dehghankhold M, Ataei S, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics  2018; 10(2): 57.
 [http://dx.doi.org/10.3390/pharmaceutics10020057 ] [PMID:  29783687]

[73]
Elsherif NI, Shamma RN, Abdelbary G. Terbinafine hydrochloride trans-ungual delivery via nanovesicular systems: in vitro characterization and ex vivo evaluation. AAPS PharmSciTech  2017; 18(2): 551-62.
 [http://dx.doi.org/10.1208/s12249-016-0528-9] [PMID:  27138036]

[74]
Abdelrahman FE, Elsayed I, Gad MK, Elshafeey AH, Mohamed MI. Response surface optimization, Ex vivo and in vivo investigation of nasal spanlastics for bioavailability enhancement and brain targeting of risperidone. Int J Pharm  2017; 530(1-2): 1-11.
 [http://dx.doi.org/10.1016/j.ijpharm.2017.07.050] [PMID:  28733244]

[75]
Ghaderi S, Ghanbarzadeh S, Mohammadhassani Z, Hamishehkar H. Formulation of gammaoryzanol-loaded nanoparticles for potential application in fortifying food products. Adv Pharm Bull  2014; 4 (Suppl. 2): 549-54.
 [PMID:  25671188]

[76]
Lasoń E, Sikora E, Ogonowski J. Influence of process parameters on properties of Nanostructured Lipid Carriers (NLC) formulation. Acta Biochim Pol  2013; 60(4): 773-7.
 [PMID:  24432330]

[77]
Fahmy UA, Ahmed OAA, Badr-Eldin SM, et al. Optimized nanostructured lipid carriers integrated into in situ nasal gel for enhancing brain delivery of flibanserin. Int J Nanomedicine  2020; 15: 5253-64.
 [http://dx.doi.org/10.2147/IJN.S258791] [PMID:  32801690]

[78]
El-Helw AR, Fahmy U. Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers. Int J Nanomedicine  2015; 10: 5797-804.
 [http://dx.doi.org/10.2147/IJN.S91556] [PMID:  26396513]

[79]
Wang N, Hsu C, Zhu L, Tseng S, Hsu JP. Influence of metal oxide nanoparticles concentration on their zeta potential. J Colloid Interface Sci  2013; 407: 22-8.
 [http://dx.doi.org/10.1016/j.jcis.2013.05.058] [PMID:  23838331]

[80]
Basha M, Abd El-Alim SH, Shamma RN, Awad GEA. Design and optimization of surfactant-based nanovesicles for ocular delivery of Clotrimazole. J Liposome Res  2013; 23(3): 203-10.
 [http://dx.doi.org/10.3109/08982104.2013.788025] [PMID:  23607316]

[81]
Uchechi O, Ogbonna JD, Attama AA. Nanoparticles for dermal and transdermal drug delivery.In: Application of nanotechnology
in drug delivery InTech.   2014; 4: pp. 193-227.
 [http://dx.doi.org/10.5772/58672]

[82]
Mazyed EA, Zakaria S. Enhancement of dissolution characteristics of clopidogrel bisulphate by proniosomes.  Int J Appl Pharmaceut 2019; pp. 77-85.
 [http://dx.doi.org/10.22159/ijap.2019v11i2.30575]

[83]
Das MK, Palei NN. Sorbitan ester niosomes for topical delivery of rofecoxib. Indian J Exp Biol  2011; 49(6): 438-5.

[84]
Garg V, Singh H, Bhatia A, et al. Systematic development of transethosomal gel system of piroxicam: Formulation optimization, in vitro evaluation, and ex vivo assessment. AAPS PharmSciTech  2017; 18(1): 58-71.
 [http://dx.doi.org/10.1208/s12249-016-0489-z] [PMID:  26868380]

[85]
Hosny KM, Hassan AH. Intranasal in situ gel loaded with saquinavir mesylate nanosized microemulsion: Preparation, characterization, and in vivo evaluation. Int J Pharm  2014; 475(1-2): 191-7.
 [http://dx.doi.org/10.1016/j.ijpharm.2014.08.064] [PMID:  25178831]

[86]
Baboota S, Shakeel F, Ahuja A, Ali J, Shafiq S. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib. Acta Pharm  2007; 57(3): 315-32.
 [http://dx.doi.org/10.2478/v10007-007-0025-5] [PMID:  17878111]

[87]
Abd-Elal RMA, Shamma RN, Rashed HM, Bendas ER. Trans-nasal zolmitriptan novasomes: in-vitro preparation, optimization and in-vivo evaluation of brain targeting efficiency. Drug Deliv  2016; 23(9): 3374-86.
 [http://dx.doi.org/10.1080/10717544.2016.1183721 ] [PMID:  27128792]

[88]
Shang Y, Inthavong K, Qiu D, Singh N, He F, Tu J. Prediction of nasal spray drug absorption influenced by mucociliary clearance. PLoS One  2021; 16(1): e0246007.
 [http://dx.doi.org/10.1371/journal.pone.0246007] [PMID:  33507973]

Cite As

Current Nanomedicine

Design Formulation of Nanospanlastic Novel Carriers as a Promising Approach to Enhanced Bioavailability in Intranasal Drug Delivery for Sinusitis: Statistical Optimization and In vitro and In vivo Characterization

Abstract

Graphical Abstract